{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:02:16Z","timestamp":1786114936096,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100023174","name":"Kementerian Pendidikan, Kebudayaan, Riset, dan Teknologi","doi-asserted-by":"publisher","award":["BU-201803201443"],"award-info":[{"award-number":["BU-201803201443"]}],"id":[{"id":"10.13039\/501100023174","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.eprac.2026.01.016","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T16:28:59Z","timestamp":1769790539000},"page":"829-837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy to Insulin Pumps for Type 1 Diabetes: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"32","author":[{"given":"Puguh","family":"Oktavian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaskia Nafisa","family":"Salma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shella","family":"Harjono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manika Putri","family":"Kunigara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Iskak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"Rahayu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayhan Alma","family":"Shafannisa Heru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sony Wibisono","family":"Mudjanarko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indah Mohd","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5180-957X","authenticated-orcid":false,"given":"Citrawati Dyah","family":"Kencono Wungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2026.01.016_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.016_bib2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","article-title":"Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study","volume":"10","author":"Gregory","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.016_bib3","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2337\/dc15-0078","article-title":"Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry","volume":"38","author":"Miller","year":"2015","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.016_bib4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2337\/dc23-2033","article-title":"Improved glycemic outcomes with diabetes technology use independent of socioeconomic status in youth with type 1 diabetes","volume":"47","author":"Lomax","year":"2024","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.016_bib5","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.016_bib6","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.016_bib7","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the north American inTandem1 study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.016_bib8","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA1c and hypoglycemia reductions at 24 and 52 weeks with Sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 Study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care"},{"issue":"24","key":"10.1016\/j.eprac.2026.01.016_bib9","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of Sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.016_bib10","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(19)30154-8","article-title":"SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks","volume":"7","author":"Taylor","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.016_bib11","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/dom.13260","article-title":"Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Yamada","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.01.016_bib12","article-title":"The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.016_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108632","article-title":"The effect of sodium-glucose cotransporter 2 inhibitors as an adjunct to insulin in patients with type 1 diabetes assessed by continuous glucose monitoring: a systematic review and meta-analysis","volume":"37","author":"Li","year":"2023","journal-title":"J Diabetes Complications"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.016_bib14","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2337\/dc20-0924","article-title":"Diabetic ketoacidosis and related events with Sotagliflozin added to insulin in adults with type 1 diabetes: a pooled analysis of the inTandem 1 and 2 studies","volume":"43","author":"Peters","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.01.016_bib15","series-title":"Cochrane handbook for systematic reviews of interventions version 6.5","author":"Higgins","year":"2024"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.016_bib16","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.eprac.2026.01.016_bib17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.016_bib18","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/s41591-022-01805-3","article-title":"Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 \u00d7 2 factorial randomized crossover trial","volume":"28","author":"Haidar","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.016_bib19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/dom.14258","article-title":"Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: the DAPADream study","volume":"23","author":"Biester","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.016_bib20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2337\/dc22-0490","article-title":"Low-Dose empagliflozin as adjunct to hybrid closed-loop insulin therapy in adults with suboptimally controlled type 1 diabetes: a randomized crossover controlled trial","volume":"46","author":"Pasqua","year":"2022","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.016_bib21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/dia.2021.0542","article-title":"Automated insulin delivery with SGLT2i combination therapy in type 1 diabetes","volume":"24","author":"Garcia-Tirado","year":"2022","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.016_bib22","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/dom.14335","article-title":"Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: a randomized, controlled, non-inferiority, crossover pilot trial","volume":"23","author":"Haidar","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.016_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/dia.2020.0079","article-title":"Effects of Sotagliflozin combined with intensive insulin therapy in young adults with poorly controlled type 1 diabetes: the JDRF Sotagliflozin Study","volume":"23","author":"Bode","year":"2021","journal-title":"Diabetes Technol Ther"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.016_bib24","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-Week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.016_bib25","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/dom.14060","article-title":"Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial","volume":"22","author":"Mathieu","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.016_bib26","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/dc15-1730","article-title":"Efficacy and safety of Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as Add-on to insulin in patients with type 1 diabetes","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.016_bib27","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2337\/dc14-2806","article-title":"Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes","volume":"38","author":"Sands","year":"2015","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.016_bib28","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3390\/pharmaceutics15071945","article-title":"The effect of additional treatment with empagliflozin or semaglutide on endothelial function and arterial stiffness in subjects with type 1 diabetes Mellitus\u2014Endis Study","volume":"15","author":"Navodnik","year":"2023","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.016_bib29","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1111\/dom.13825","article-title":"Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: the inTandem4 trial","volume":"21","author":"Baker","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.016_bib30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2337\/dc24-0212","article-title":"Combination SGLT2 inhibitor and Glucagon receptor antagonist therapy in type 1 diabetes: a randomized clinical trial","volume":"48","author":"Boeder","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.016_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","article-title":"Continuous glucose monitoring and metrics for clinical trials: an international consensus statement","volume":"11","author":"Battelino","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.016_bib32","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.2337\/dc08-2326","article-title":"Preservation of \u03b2-Cell function in autoantibody-positive youth with diabetes","volume":"32","author":"Greenbaum","year":"2009","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.016_bib33","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1177\/19322968231176302","article-title":"Participant experiences of low-dose empagliflozin use as adjunct therapy to hybrid closed loop: findings from a randomized controlled trial","volume":"17","author":"Pasqua","year":"2023","journal-title":"J Diabetes Sci Technol"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.016_bib34","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2337\/diab.35.12.1326","article-title":"Insulin dose-response characteristics for suppression of glycerol release and conversion to glucose in humans","volume":"35","author":"Nurjhan","year":"1986","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.016_bib35","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa200","article-title":"Evolving evidence of diabetic ketoacidosis in patients taking sodium-glucose cotransporter 2 inhibitors","volume":"105","author":"Fleming","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.016_bib36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1152\/ajplegacy.1955.184.1.91","article-title":"Renal tubular reabsorption of acetoacetate, inorganic sulfate and inorganic phosphate in the dog as affected by glucose and phlorizin","volume":"184","author":"Cohen","year":"1956","journal-title":"Am J Physiol"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.016_bib37","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","article-title":"International Consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium\u2013glucose cotransporter (SGLT) inhibitors","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.016_bib38","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1089\/dia.2021.0548","article-title":"Insulin pump infusion set failures associated with prolonged hyperglycemia: frequency and relationship to age and type of infusion set during 22,741 infusion set wears","volume":"24","author":"Kanapka","year":"2022","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.016_bib39","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/19322968211008185","article-title":"Feasibility of continuous ketone monitoring in subcutaneous tissue using a ketone sensor","volume":"15","author":"Alva","year":"2021","journal-title":"J Diabetes Sci Technol"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.016_bib40","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2337\/dc20-0567","article-title":"Clinical impact of residual C-Peptide secretion in type 1 diabetes on glycemia and microvascular complications","volume":"44","author":"Jeyam","year":"2021","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.016_bib41","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1111\/dom.16268","article-title":"A comparison of ultra-rapid and rapid insulin in automated insulin delivery for type 1 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Oktavian","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.016_bib42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/193229681000400127","article-title":"Amperometric glucose sensors: sources of error and potential benefit of redundancy","volume":"4","author":"Castle","year":"2010","journal-title":"J Diabetes Sci Technol"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.016_bib43","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1177\/19322968211035411","article-title":"Strategically playing with fire: SGLT inhibitors as possible adjunct to closed-loop insulin therapy","volume":"15","author":"Pasqua","year":"2021","journal-title":"J Diabetes Sci Technol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26000339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26000339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T23:28:25Z","timestamp":1785972505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26000339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1530891X26000339"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.01.016","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy to Insulin Pumps for Type 1 Diabetes: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}